1 completed, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Stage 0is Ureter Cancer AJCC v8: new trials by email Literature Review of Stage 0is Ureter Cancer AJCC v8 trials Research Report on Stage 0is Ureter Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study Gemcitabine Hydrochloride - Stage 0a Renal Pelvis and Ureter Cancer AJCC v8, Stage 0a Renal Pelvis Cancer AJCC v8 | Phase 2 | Terminated | Mayo Clinic | 25 | 2020-06-05 | 2023-08-08 |
| Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Erlotinib Hydrochloride - Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 34 | 2008-06-10 | 2020-09-10 |
Ureteral Neoplasms (2) · Urethral Neoplasms (1) · Urinary Bladder Neoplasms (1)
Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Ureteral Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2) · Urologic Neoplasms (2) · Urethral Diseases (1) · Urinary Bladder Diseases (1)
Erlotinib Hydrochloride (1) · Gemcitabine (1)
M.D. Anderson Cancer Center (1) · Mayo Clinic (1)
United States (2)
Arlene Siefker-Radtke (1) · Stephen A Boorjian (1)
P30CA016672 (1)